PAVmed (PAVM) Q2 2024 earnings summary

Executive summary

• Subsidiaries are advancing toward independent financing, with Lucid Diagnostics self-sustaining and Veris Health and PMX Incubator progressing on funding rounds and product development.

• Lucid Diagnostics achieved record EsoGuard test volumes in Q2 2024, with a 31% sequential and 44% year-over-year increase, driving a 514% year-over-year revenue increase.

• Veris Health launched a pilot program at Ohio State University, enrolling patients and nearing financing for its implantable monitor project.

• PMX Incubator is focused on raising capital for PortIO, a device for long-term bone marrow access, with a completed first in-human study and a clear path to FDA clearance.

• The company continues to focus on commercial expansion of EsoGuard and strategic partnerships for Veris, but substantial doubt exists about its ability to continue as a going concern due to recurring losses and negative cash flows.

Financial highlights

• Q2 2024 revenue was $1.0 million, flat sequentially but up 514% year-over-year, with six-month revenue at $2.0 million.

• Cash and cash equivalents stood at $25.5 million as of June 30, 2024, up from $19.6 million at year-end 2023, with $11.6 million added from Lucid financing.

• Average quarterly burn rate over the last four quarters was $11.6 million.

• Non-GAAP loss for Q2 2024 was $7.7 million, or $(0.84) per share; GAAP net loss attributable to common stockholders was $10.9 million, or $(1.19) per share.

• Operating expenses for Q2 2024 were $14.6 million, including $1.9 million in stock-based compensation.

Outlook and guidance

• Ability to fund operations beyond one year depends on revenue growth, reimbursement improvements, and successful subsidiary financings.

• Veris Health expects to complete its pilot and secure financing soon, targeting FDA submission for its implantable monitor by mid-2025.

• The company expects continued recurring losses and negative cash flows, with ongoing funding needs for operations and debt obligations.

• Additional contracts with large academic centers are expected to accelerate after the Veris pilot concludes.

• Strategy focuses on enabling subsidiaries to become independently financeable and leverage shared infrastructure.